Market expert Amit Khurana offers insights on key corporate and regulatory developments. Sun Pharma's acquisition is seen as strategically ...

US company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai H...

Sun Pharmaceutical is making its biggest move yet with a $13 billion offer for Organon & Co. This ambitious bid aims to transform the India...

Bain Capital has emerged as the frontrunner to acquire Vitabiotics, as rival bidders TPG Capital and EQT exit the process, potentially lowe...

Sun Pharmaceutical Industries is nearing a $12 billion acquisition of Organon & Co, marking its most significant overseas expansion. Follow...

The company has issued a letter to the Taro board with a proposal containing a non-binding indication of interest to acquire all of the out...

Speciality drugs refer to high cost, high complexity medicines, including biologicals, for the treatment of complex or rare conditions. The...

Drugmakers have reported impairments, reduced revenue guidance, or stretched the payback time.

Sun Pharma is eyeing a controlling stake in UK based Bolt Equity Limited which is backed by AAC Capital.

Sun management, in the post-results earnings call, admitted Ranbaxy's integration is likely to take more time than originally envisaged.

Since 2013, Sun Pharma stock has doubled from below Rs 400 to a level closer to the Rs 1,000 mark – making Dilip Shanghvi, the richest bill...

Multinational firms have been usually acquiring Indian drugmakers to expand in the country and leverage their manufacturing facilities.

Sun Pharma had acquired majority stake (66%) in the Israeli generic firm Taro Pharma in 2007 for $450 million, but got control of the compa...

Sun has had its fair share of problems but has managed to extricate itself quickly and turn things around.

Israeli firm Taro Pharmaceutical Industries Ltd said it postponed a meeting of shareholders to consider the company's proposed merger with ...

Sun Pharma's proposed buyout of Taro Pharmaceuticals might have been "killed" by the Israeli company's exceptional Q4 performance, said med...

Second-largest overseas buyout by an Indian pharma company will give Sun an edge in North America where Israeli generics player records 90%...